Product Datasheet

AUR-1545

Catalog No. **BP-02276** · CAS **3031593-79-7** · Form **free base** · Physical state **solid** · Color **Off-white to light yellow** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
PROTACs; Histone Acetyltransferase	**Cancer**

Molecular formula	$C_{41}H_{50}BrN_9O_5$
Molecular weight	**828.7970**

STRUCTURE



DESCRIPTION

AUR1545 is a selective KAT2A/KAT2B ((GCN5/PCAF)) PROTAC degrader that induces monocyte differentiation and inhibits the growth of acute myeloid leukemia cells. AUR1545 inhibits cell growth, induces epithelial differentiation and suppresses tumor growth in small cell lung cancer models. AUR1545 inhibits cell growth and induces differentiation in neuroendocrine prostate cancer cells and primary patient-derived organoids. AUR1545 is applicable to research related to acute myeloid leukemia, small cell lung cancer and neuroendocrine prostate cancer.

BIOLOGICAL ACTIVITY

In Vitro

AUR1545 potently degrades KAT2A/KAT2B and inhibits the growth of NCI-H1048, LASCPC-01 and MOLM-13 cells (1.5 nM, 5 nM, and 1.2 nM, respectively); its DC50 values against KAT2A in the three cell lines are 0.01 nM, 0.67 nM, and 0.11 nM respectively, while its DC50 values against KAT2B are 1.5 nM, 0.16 nM, and 0.075 nM respectively.

AUR1545 (0.001-100 nM; 48 h-8 d) induces differentiation in MOLM-13 cells, with an EC50 of 0.3 nM for CD86.

AUR1545 (0.01-100 nM; 24 h-7 d) induces epithelial differentiation in LASCPC-01 cells.

AUR1545 (0.01-1000 nM; 72 h-21 d) induces microglial differentiation in primary organoids derived from NEPC patients.

In Vivo

AUR1545 (30 mg/kg; i.p.; once per week) induces 70% tumor growth inhibition and upregulates epithelial differentiation in NCI-H1048 tumor-bearing Nude balb/c mice.

SOLUBILITY

Soluble in DMSO

In vitro	DMSO : 100 mg/mL

REFERENCES

[1]. Straley K S, et al. Potent and selective degradation of KAT2A and KAT2B induces profound cell state changes and inhibits growth of AML, SCLC and NEPC model systems[J]. Cancer Research, 2024, 84(6_Supplement): 5795-5795.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com